cMET Exon 14 Skipping: From the Structure to the Clinic - ScienceDirect
Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study Yu Y, Zhang Q, Zhang J, Lu S - J Can Res Ther
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Lung cancer with MET exon 14 skipping mutation | LCTT
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
![MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67fdcd54f931874b6e6ffa4ffca44de1124ea7f0/5-Figure1-1.png "MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar")
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar
Diagnosis and Discussion -- Case 1068
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - Lung Cancer
Figure 2 from MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. | Semantic Scholar
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram
Lung cancer with MET exon 14 skipping mutation | LCTT
An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology | Laboratory Investigation
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. - Abstract - Europe PMC
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer
MET Mutation Associated with Responsiveness to Crizotinib. - Abstract - Europe PMC
Mutations as Predictive Biomarkers for Adenocarcinoma | Oncohema Key
Frontiers | Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study | Oncology
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
